Krebs Biochemicals holds 34th AGM on Sep 29, 2026, discusses financial statements and RPTs.
Krebs Biochemicals & Industries Limited conducted its 34th AGM on September 29, 2026. Key agenda items included approving financial statements for FY26, reappointing directors, and approving related party transactions with Ipca Laboratories Limited. E-voting was conducted from September 25-28, 2026.
The announcement details the proceedings of a routine Annual General Meeting. No new financial information, strategic decisions, or material events that would significantly impact the company's operations or stock price were disclosed.
The announcement pertains to the proceedings of an Annual General Meeting, which is a routine corporate event. No specific financial outcomes or significant business developments were detailed that would warrant a positive or negative sentiment.
Krebs Biochemicals & Industries Limited held its 34th Annual General Meeting (AGM) on Tuesday, September 29, 2026, commencing at 11:30 a.m. The meeting was conducted through Video Conferencing / Other Audio Visual Means (VC/OAVM).
All directors, including the Chairman of the Audit and Nomination & Remuneration Committee, Chief Financial Officer, and Company Secretary, were present. Representatives from the Statutory Auditors, Secretarial Auditors, and Scrutinizer also attended virtually. The Chairman, Dr. R T Ravi, confirmed the presence of the quorum.
The agenda items requiring member approval included the Audited Balance Sheet, Statement of Profit & Loss, and Cash Flow Statement for the financial year ended March 31, 2026. Additionally, the reappointment of directors Dr. R T Ravi and Mr. Manish Kumar Jain, approval for Related Party Transactions with Ipca Laboratories Limited, and ratification of the Cost Auditors' remuneration were discussed.
Electronic voting was facilitated from September 25, 2026, to September 28, 2026. The Company Secretary informed members about the availability of statutory registers and other relevant documents on the company's website. The meeting concluded at 12:15 p.m. after a vote of thanks, with the results of the voting to be declared and posted on the company website upon receipt of the scrutinizer's report.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.